BW

09
Ene
By MetroLatinoUSA
BW

PowerSchool Accelerates International Expansion with Plans to Open First Middle East & Africa Office

UAE office will strengthen PowerSchool’s growing relationships with customers across the Middle East and Africa FOLSOM, Calif.--(BUSINESS WIRE)--PowerSchool (NYSE: PWSC), the leading provider of cloud-based software for K-12 education in North America, announced its accelerated international expansion plans to open its first Middle East & Africa (MEA) Office in Dubai,…
Leer más...
08
Ene
By MetroLatinoUSA
BW

BIOLINERX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioLineRx Ltd. (“BioLineRx” or the “Company”) (NASDAQ: BLRX) in the United States District Court for the District of New Jersey on behalf of all persons and…
Leer más...
08
Ene
By MetroLatinoUSA
BW

G-III ALERT: Bragar Eagel & Squire, P.C. is Investigating G-III Apparel Group, Ltd. on Behalf of G-III Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against G-III Apparel Group, Ltd. (“G-III” or the “Company”) (NASDAQ: GIII) on behalf of G-III stockholders. Our investigation concerns whether G-III has violated the federal securities laws and/or engaged in other unlawful…
Leer más...
08
Ene
By MetroLatinoUSA
BW

Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced updated results following the completion of its Phase 2 clinical study using GX-188E, its first-in-class proprietary DNA vaccine, in…
Leer más...
08
Ene
By MetroLatinoUSA
BW

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange Rate**) – – Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – – Maintained Strong Balance Sheet with Year-End Cash…
Leer más...
¡Síguenos en Facebook!
¡Síguenos en Twitter!